Matched molecular pair analysis: Significance and the impact of experimental uncertainty

Journal of Medicinal Chemistry

Volumn 57, Issue 9, 2014, Pages 3786-3802

  Kramer, Christian ^a   Fuchs, Julian E ^a   Whitebread, Steven ^b   Gedeck, Peter ^c   Liedl, Klaus R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHEMICAL ANALYSIS; EXPERIMENT; MEDICINAL CHEMISTRY; PREDICTION; STATISTICAL ANALYSIS; UNCERTAINTY;

CHEMISTRY, PHARMACEUTICAL; DATABASES, FACTUAL; INFORMATION STORAGE AND RETRIEVAL; UNCERTAINTY;

EID: 84900329790     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500317a     Document Type: Article

References (92)

1. Sheridan, R. P.; Hunt, P.; Culberson, J. C. Molecular Transformations as a Way of Finding and Exploiting Consistent Local QSAR J. Chem. Inf. Model. 2006, 46, 180-192
2. Sheridan, R. P. The Most Common Chemical Replacements in Drug-like Compounds J. Chem. Inf. Comput. Sci. 2002, 42, 103-108
3. Kenny, P. W.; Sadowski, J. Structure Modification in Chemical Databases. In Chemoinformatics in Drug Discovery; Oprea, T. I., Ed.; Wiley-VCH: Weinheim, Germany, 2005; pp 271-285.
4. Leach, A. G.; Jones, H. D.; Cosgrove, D. A.; Kenny, P. W.; Ruston, L.; MacFaul, P.; Wood, J. M.; Colclough, N.; Law, B. Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure J. Med. Chem. 2006, 49, 6672-6682
5. Dossetter, A. G.; Griffen, E. J.; Leach, A. G. Matched Molecular Pair Analysis in Drug Discovery Drug Discovery Today 2013, 18, 724-731
6. Griffen, E.; Leach, A. G.; Robb, G. R.; Warner, D. J. Matched Molecular Pairs as a Medicinal Chemistry Tool J. Med. Chem. 2011, 54, 7739-7750
7. Nicola, G.; Liu, T.; Gilson, M. K. Public Domain Databases for Medicinal Chemistry J. Med. Chem. 2012, 55, 6987-7002
8. Dossetter, A. G. A Statistical Analysis of in Vitro Human Microsomal Metabolic Stability of Small Phenyl Group Substituents, Leading to Improved Design Sets for Parallel SAR Exploration of a Chemical Series Bioorg. Med. Chem. 2010, 18, 4405-4414
9. Dossetter, A. G.; Douglas, A.; ODonnell, C. A Matched Molecular Pair Analysis of in Vitro Human Microsomal Metabolic Stability Measurements for Heterocyclic Replacements of Di-Substituted Benzene Containing Compounds - Identification of Those Isosteres More Likely To Have Beneficial Effects Med. Chem. Commun. 2012, 3, 1164-1169
10. Papadatos, G.; Alkarouri, M.; Gillet, V. J.; Willett, P.; Kadirkamanathan, V.; Luscombe, C. N.; Bravi, G.; Richmond, N. J.; Pickett, S. D.; Hussain, J.; Pritchard, J. M.; Cooper, A. W. J.; Macdonald, S. J. F. Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and Lipophilicity J. Chem. Inf. Model. 2010, 50, 1872-1886
11. Schultes, S.; Graaf, C. de; Berger, H.; Mayer, M.; Steffen, A.; Haaksma, E. E. J.; Esch, I. J. P. de; Leurs, R.; Krämer, O. A Medicinal Chemistry Perspective on Melting Point: Matched Molecular Pair Analysis of the Effects of Simple Descriptors on the Melting Point of Drug-like Compounds Med. Chem. Commun. 2012, 3, 584-591
12. Gleeson, P.; Bravi, G.; Modi, S.; Lowe, D. ADMET Rules of Thumb II: A Comparison of the Effects of Common Substituents on a Range of ADMET Parameters Bioorg. Med. Chem. 2009, 17, 5906-5919
13. Keefer, C. E.; Chang, G.; Kauffman, G. W. Extraction of Tacit Knowledge from Large ADME Data Sets via Pairwise Analysis Bioorg. Med. Chem. 2011, 19, 3739-3749
14. Birch, A. M.; Kenny, P. W.; Simpson, I.; Whittamore, P. R. O. Matched Molecular Pair Analysis of Activity and Properties of Glycogen Phosphorylase Inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 850-853
15. Hussain, J.; Rea, C. Computationally Efficient Algorithm To Identify Matched Molecular Pairs (MMPs) in Large Data Sets J. Chem. Inf. Model. 2010, 50, 339-348
16. Warner, D. J.; Griffen, E. J.; St-Gallay, S. A. WizePairZ: A Novel Algorithm To Identify, Encode, and Exploit Matched Molecular Pairs with Unspecified Cores in Medicinal Chemistry J. Chem. Inf. Model. 2010, 50, 1350-1357
17. Dimova, D.; Hu, Y.; Bajorath, J. Matched Molecular Pair Analysis of Small Molecule Microarray Data Identifies Promiscuity Cliffs and Reveals Molecular Origins of Extreme Compound Promiscuity J. Med. Chem. 2012, 55, 10220-10228
18. Hu, X.; Hu, Y.; Vogt, M.; Stumpfe, D.; Bajorath, J. MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs J. Chem. Inf. Model. 2012, 52, 1138-1145
19. Wassermann, A. M.; Bajorath, J. Large-Scale Exploration of Bioisosteric Replacements on the Basis of Matched Molecular Pairs Future Med. Chem. 2011, 3, 425-436
20. Wirth, M.; Zoete, V.; Michielin, O.; Sauer, W. H. B. SwissBioisostere: A Database of Molecular Replacements for Ligand Design Nucleic Acids Res. 2012, 41, D1137-D1143
21. Weber, J.; Achenbach, J.; Moser, D.; Proschak, E. VAMMPIRE: A Matched Molecular Pairs Database for Structure-Based Drug Design and Optimization J. Med. Chem. 2013, 56, 5203-5207
22. Papadatos, G.; Bodkin, M. J.; Gillet, V. J.; Willett, P. Mining for Context-Sensitive Bioisosteric Replacements in Large Chemical Databases. In Bioisosteres in Medicinal Chemistry; Brown, N., Ed.; Wiley-VCH: Weinheim, Germany, 2012; pp 103-127.
23. Hajduk, P. J.; Sauer, D. R. Statistical Analysis of the Effects of Common Chemical Substituents on Ligand Potency J. Med. Chem. 2008, 51, 553-564
24. Schönbrodt, F. D.; Perugini, M. At What Sample Size Do Correlations Stabilize? J. Res. Pers. 2013, 47, 609-612
25. Upton, G. J. G. A Dictionary of Statistics, 2 nd ed.; Oxford University Press: Oxford, U.K., 2008.
26. Kramer, C.; Kalliokoski, T.; Gedeck, P.; Vulpetti, A. The Experimental Uncertainty of Heterogeneous Public Ki Data J. Med. Chem. 2012, 55, 5165-5173
27. 50 Data - A Statistical Analysis PLoS One 2013, 8, e61007
28. Dunn, O. J. Multiple Comparisons among Means J. Am. Stat. Assoc. 1961, 56, 52-64
29. Warmke, J. W.; Ganetzky, B. A Family of Potassium Channel Genes Related to Eag in Drosophila and Mammals Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3438-3442
30. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG Potassium Channels and Cardiac Arrhythmia Nature 2006, 440, 463-469
31. Sanguinetti, M. C.; Jiang, C.; Curran, M. E.; Keating, M. T. A Mechanistic Link between an Inherited and an Acquird Cardiac Arrthytmia: HERG Encodes the IKr Potassium Channel Cell 1995, 81, 299-307
32. Trudeau, M. C.; Warmke, J. W.; Ganetzky, B.; Robertson, G. A. HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family Science 1995, 269, 92-95
33. Aronov, A. M. Predictive in Silico Modeling for hERG Channel Blockers Drug Discovery Today 2005, 10, 149-155
34. Stansfeld, P. J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J. S.; Sutcliffe, M. J. Drug Block of the hERG Potassium Channel: Insight from Modeling Proteins 2007, 68, 568-580
35. + Channels: Structure, Function, and Clinical Significance Physiol. Rev. 2012, 92, 1393-1478
36. Witchel, H. J. Drug-Induced hERG Block and Long QT Syndrome Cardiovasc. Ther. 2011, 29, 251-259
37. Hancox, J. C.; McPate, M. J.; El Harchi, A.; Zhang, Y. H. The hERG Potassium Channel and hERG Screening for Drug-Induced Torsades de Pointes Pharmacol. Ther. 2008, 119, 118-132
38. Ponti, F. D.; Poluzzi, E.; Montanaro, N. Organising Evidence on QT Prolongation and Occurrence of Torsades de Pointes with Non-Antiarrhythmic Drugs: A Call for Consensus Eur. J. Clin. Pharmacol. 2001, 57, 185-209
39. Czodrowski, P. hERG Me Out J. Chem. Inf. Model. 2013, 53, 2240-2251
40. Kramer, C.; Beck, B.; Kriegl, J. M.; Clark, T. A Composite Model for hERG Blockade ChemMedChem 2008, 3, 254-265
41. Raschi, E.; Ceccarini, L.; De Ponti, F.; Recanatini, M. hERG-Related Drug Toxicity and Models for Predicting hERG Liability and QT Prolongation Expert Opin. Drug Metab. Toxicol. 2009, 5, 1005-1021
42. Nisius, B.; Göller, A. H. Similarity-Based Classifier Using Topomers To Provide a Knowledge Base for hERG Channel Inhibition J. Chem. Inf. Model. 2009, 49, 247-256
43. Nisius, B.; Göller, A. H.; Bajorath, J. Combining Cluster Analysis, Feature Selection and Multiple Support Vector Machine Models for the Identification of Human Ether-a-go-go Related Gene Channel Blocking Compounds Chem. Biol. Drug Des. 2009, 73, 17-25
44. Hansen, K.; Rathke, F.; Schroeter, T.; Rast, G.; Fox, T.; Kriegl, J. M.; Mika, S. Bias-Correction of Regression Models: A Case Study on hERG Inhibition J. Chem. Inf. Model. 2009, 49, 1486-1496
45. + Current J. Physiol. Sci. 2008, 58, 459-470
46. + Channel Inhibition by Combining 3D-QSAR Pharmacophore and 2D-QSAR Models J. Mol. Model. 2012, 18, 1023-1036
47. Pearlstein, R. A.; Vaz, R. J.; Kang, J.; Chen, X.-L.; Preobrazhenskaya, M.; Shchekotikhin, A. E.; Korolev, A. M.; Lysenkova, L. N.; Miroshnikova, O. V.; Hendrix, J.; Rampe, D. Characterization of HERG Potassium Channel Inhibition Using CoMSiA 3D QSAR and Homology Modeling Approaches Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835
48. + Channel: Application to Ligand Binding Bioorg. Med. Chem. Lett. 2005, 15, 1737-1741
49. Farid, R.; Day, T.; Friesner, R. A.; Pearlstein, R. A. New Insights about HERG Blockade Obtained from Protein Modeling, Potential Energy Mapping, and Docking Studies Bioorg. Med. Chem. 2006, 14, 3160-3173
50. Thai, K.-M.; Ecker, G. F. A Binary QSAR Model for Classification of hERG Potassium Channel Blockers Bioorg. Med. Chem. 2008, 16, 4107-4119
51. Doddareddy, M. R.; Klaasse, E. C.; Shagufta; IJzerman, A. P.; Bender, A. Prospective Validation of a Comprehensive in Silico hERG Model and Its Applications to Commercial Compound and Drug Databases ChemMedChem 2010, 5, 716-729
52. + Channel. A Model for Bad Behavior J. Med. Chem. 2003, 46, 2017-2022
53. Roche, O.; Trube, G.; Zuegge, J.; Pflimlin, P.; Alanine, A.; Schneider, G. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries ChemBioChem 2002, 3, 455-459
54. Seierstad, M.; Agrafiotis, D. K. A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set Chem. Biol. Drug Des. 2006, 67, 284-296
55. Gavaghan, C. L.; Arnby, C. H.; Blomberg, N.; Strandlund, G.; Boyer, S. Development, Interpretation and Temporal Evaluation of a Global QSAR of hERG Electrophysiology Screening Data J. Comput.-Aided Mol. Des. 2007, 21, 189-206
56. Cianchetta, G.; Li, Y.; Kang, J.; Rampe, D.; Fravolini, A.; Cruciani, G.; Vaz, R. J. Predictive Models for hERG Potassium Channel Blockers Bioorg. Med. Chem. Lett. 2005, 15, 3637-3642
57. + Channel Blockers Bioorg. Med. Chem. 2004, 12, 2307-2315
58. Song, M.; Clark, M. Development and Evaluation of an in Silico Model for hERG Binding J. Chem. Inf. Model. 2006, 46, 392-400
59. + Channel Blockers J. Med. Chem. 2002, 45, 3844-3853
60. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A. Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-Related Gene Potassium Channel J. Pharmacol. Exp. Ther. 2002, 301, 427-434
61. Aronov, A. M. Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers J. Med. Chem. 2006, 49, 6917-6921
62. Johnson, S. R.; Yue, H.; Conder, M. L.; Shi, H.; Doweyko, A. M.; Lloyd, J.; Levesque, P. Estimation of hERG Inhibition of Drug Candidates Using Multivariate Property and Pharmacophore SAR Bioorg. Med. Chem. 2007, 15, 6182-6192
63. R. Development Core Team. R: A Language and Environment for Statistical Computing; R. Foundation for Statistical Computing: Vienna, Austria, 2008.
64. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery Nucleic Acids Res. 2011, 40, D1100-D1107
65. Kramer, C.; Lewis, R. QSARs, Data and Error in the Modern Age of Drug Discovery Curr. Top. Med. Chem. 2012, 12, 1896-1902
66. Kalliokoski, T.; Kramer, C.; Vulpetti, A. Quality Issues with Public Domain Chemogenomics Data Mol. Inf. 2013, 32, 898-905
67. Landrum, G.; RDKit: Cheminformatics and Machine Learning Software. www.rdkit.org, 2013.
68. Brown, N. Bioisosteres in Medicinal Chemistry; Wiley-VCH: Weinheim, Germany, 2012.
69. Waring, M. J.; Johnstone, C. A Quantitative Assessment of hERG Liability as a Function of Lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
70. Springer, C.; Sokolnicki, K. L. A Fingerprint Pair Analysis of hERG Inhibition Data Chem. Cent. J. 2013, 7, 167
71. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups J. Med. Chem. 2006, 49, 5029-5046
72. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods J. Phys. Chem. A 1998, 102, 3762-3772
73. Kawai, Y.; Tsukamoto, S.; Ito, J.; Akimoto, K.; Takahashi, M. A Risk Assessment of Human Ether-a-Go-Go-Related Gene Potassium Channel Inhibition by Using Lipophilicity and Basicity for Drug Discovery Chem. Pharm. Bull. 2011, 59, 1110-1116
74. Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
75. Fournier, P.-A.; Arbour, M.; Cauchon, E.; Chen, A.; Chefson, A.; Ducharme, Y.; Falgueyret, J.-P.; Gagné, S.; Grimm, E.; Han, Y.; Houle, R.; Lacombe, P.; Lévesque, J.-F.; MacDonald, D.; Mackay, B.; McKay, D.; Percival, M. D.; Ramtohul, Y.; St-Jacques, R.; Toulmond, S. Design and Synthesis of Potent, Isoxazole-containing Renin Inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 2670-2674
76. Moree, W. J.; Jovic, F.; Coon, T.; Yu, J.; Li, B.-F.; Tucci, F. C.; Marinkovic, D.; Gross, R. S.; Malany, S.; Bradbury, M. J.; Hernandez, L. M.; OBrien, Z.; Wen, J.; Wang, H.; Hoare, S. R. J.; Petroski, R. E.; Sacaan, A.; Madan, A.; Crowe, P. D.; Beaton, G. Novel Benzothiophene H1-Antihistamines for the Treatment of Insomnia Bioorg. Med. Chem. Lett. 2010, 20, 2316-2320
77. Berglund, S.; Egner, B. J.; Gradén, H.; Gradén, J.; Morgan, D. G. A.; Inghardt, T.; Giordanetto, F. Optimization of 2-Piperidin-4-yl- acetamides as Melanin-Concentrating Hormone Receptor 1 (MCH-R1) Antagonists: Designing out hERG Inhibition Bioorg. Med. Chem. Lett. 2009, 19, 4268-4273
78. Pastor, J.; Oyarzabal, J.; Saluste, G.; Alvarez, R. M.; Rivero, V.; Ramos, F.; Cendón, E.; Blanco-Aparicio, C.; Ajenjo, N.; Cebriá, A.; Albarrán, M. I.; Cebrián, D.; Corrionero, A.; Fominaya, J.; Montoya, G.; Mazzorana, M. Hit to Lead Evaluation of 1,2,3-Triazolo[4,5- b ]pyridines as PIM Kinase Inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 1591-1597
79. Li, B.-F.; Moree, W. J.; Yu, J.; Coon, T.; Zamani-Kord, S.; Malany, S.; Jalali, K.; Wen, J.; Wang, H.; Yang, C.; Hoare, S. R. J.; Petroski, R. E.; Madan, A.; Crowe, P. D.; Beaton, G. Selectivity Profiling of Novel Indene H1-Antihistamines for the Treatment of Insomnia Bioorg. Med. Chem. Lett. 2010, 20, 2629-2633
80. Fox, B. M.; Natero, R.; Richard, K.; Connors, R.; Roveto, P. M.; Beckmann, H.; Haller, K.; Golde, J.; Xiao, S.-H.; Kayser, F. Novel Pyrrolidine Melanin-Concentrating Hormone Receptor 1 Antagonists with Reduced hERG Inhibition Bioorg. Med. Chem. Lett. 2011, 21, 2460-2467
81. + Channel J. Med. Chem. 2008, 51, 4021-4029
82. Zhang, X.; Hufnagel, H.; Hou, C.; Opas, E.; McKenney, S.; Crysler, C.; ONeill, J.; Johnson, D.; Sui, Z. Design, Synthesis and SAR of Indazole and Benzoisoxazole Containing 4-Azetidinyl-1-aryl-cyclohexanes as CCR2 Antagonists Bioorg. Med. Chem. Lett. 2011, 21, 6042-6048
83. Magee, T. V.; Ripp, S. L.; Li, B.; Buzon, R. A.; Chupak, L.; Dougherty, T. J.; Finegan, S. M.; Girard, D.; Hagen, A. E.; Falcone, M. J.; Farley, K. A.; Granskog, K.; Hardink, J. R.; Huband, M. D.; Kamicker, B. J.; Kaneko, T.; Knickerbocker, M. J.; Liras, J. L.; Marra, A.; Medina, I.; Nguyen, T.-T.; Noe, M. C.; Obach, R. S.; ODonnell, J. P.; Penzien, J. B.; Reilly, U. D.; Schafer, J. R.; Shen, Y.; Stone, G. G.; Strelevitz, T. J.; Sun, J.; Tait-Kamradt, A.; Vaz, A. D. N.; Whipple, D. A.; Widlicka, D. W.; Wishka, D. G.; Wolkowski, J. P.; Flanagan, M. E. Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections J. Med. Chem. 2009, 52, 7446-7457
84. Ray, P.; Wright, J.; Adam, J.; Bennett, J.; Boucharens, S.; Black, D.; Cook, A.; Brown, A. R.; Epemolu, O.; Fletcher, D.; Haunso, A.; Huggett, M.; Jones, P.; Laats, S.; Lyons, A.; Mestres, J.; de Man, J.; Morphy, R.; Rankovic, Z.; Sherborne, B.; Sherry, L.; van Straten, N.; Westwood, P.; Zaman, G. Z. R. Fragment-Based Discovery of 6-Substituted Isoquinolin-1-amine Based ROCK-I Inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 97-101
85. Graham, J. M.; Coughenour, L. L.; Barr, B. M.; Rock, D. L.; Nikam, S. S. 1-Aminoindanes as Novel Motif with Potential Atypical Antipsychotic Properties Bioorg. Med. Chem. Lett. 2008, 18, 489-493
86. Elliott, J. M.; Carling, R. W.; Chicchi, G. G.; Crawforth, J.; Hutson, P. H.; Jones, A. B.; Kelly, S.; Marwood, R.; Meneses-Lorente, G.; Mezzogori, E.; Murray, F.; Rigby, M.; Royo, I.; Russell, M. G. N.; Shaw, D.; Sohal, B.; Tsao, K. L.; Williams, B. N ′,2-Diphenylquinoline-4-carbohydrazide Based NK3 Receptor Antagonists II Bioorg. Med. Chem. Lett. 2006, 16, 5752-5756
87. Nagase, T.; Mizutani, T.; Ishikawa, S.; Sekino, E.; Sasaki, T.; Fujimura, T.; Ito, S.; Mitobe, Y.; Miyamoto, Y.; Yoshimoto, R.; Tanaka, T.; Ishihara, A.; Takenaga, N.; Tokita, S.; Fukami, T.; Sato, N. Synthesis, Structure-Activity Relationships, and Biological Profiles of a Quinazolinone Class of Histamine H3 Receptor Inverse Agonists J. Med. Chem. 2008, 51, 4780-4789
88. Mizutani, T.; Nagase, T.; Ito, S.; Miyamoto, Y.; Tanaka, T.; Takenaga, N.; Tokita, S.; Sato, N. Development of Novel 2-[4-(Aminoalkoxy)phenyl]-4(3 H)-quinazolinone Derivatives as Potent and Selective Histamine H3 Receptor Inverse Agonists Bioorg. Med. Chem. Lett. 2008, 18, 6041-6045
89. Rowley, M.; Hallett, D. J.; Goodacre, S.; Moyes, C.; Crawforth, J.; Sparey, T. J.; Patel, S.; Marwood, R.; Patel, S.; Thomas, S.; Hitzel, L.; OConnor, D.; Szeto, N.; Castro, J. L.; Hutson, P. H.; MacLeod, A. M. 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists J. Med. Chem. 2001, 44, 1603-1614
90. Methot, J. L.; Hamblett, C. L.; Mampreian, D. M.; Jung, J.; Harsch, A.; Szewczak, A. A.; Dahlberg, W. K.; Middleton, R. E.; Hughes, B.; Fleming, J. C.; Wang, H.; Kral, A. M.; Ozerova, N.; Cruz, J. C.; Haines, B.; Chenard, M.; Kenific, C. M.; Secrist, J. P.; Miller, T. A. SAR Profiles of Spirocyclic Nicotinamide Derived Selective HDAC1/HDAC2 Inhibitors (SHI-1:2) Bioorg. Med. Chem. Lett. 2008, 18, 6104-6109
91. Zachariae, U.; Giordanetto, F.; Leach, A. G. Side Chain Flexibilities in the Human Ether-a-go-go Related Gene Potassium Channel (hERG) Together with Matched-Pair Binding Studies Suggest a New Binding Mode for Channel Blockers J. Med. Chem. 2009, 52, 4266-4276
92. Kenny, P. W.; Montanari, C. A. Inflation of Correlation in the Pursuit of Drug-likeness J. Comput. Aided Mol. Des. 2013, 27, 1-13